1. age \< 18 years old. 2. inability to obtain informed consent. 3. patient's impaired consciousness in opinion of investigator. 4. swallowing difficulties before sars-cov 2 infection or related to sasrs-cov 2 infection (eg. caused by dyspnea). 5. severe food allergy. 6. at least 7 points in covid-19 performance status. 7. patients, who need blood transfusion in the day of study inclusion. 8. significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before covid 19 diagnosis. 9. stoma, perforation or abscess located in gastrointestinal tract area in the past. 10. clinical significant systemic or localised infections, other than covid 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect. 11. severe cardiac failure (nyha iii or more) before covid 19 diagnosis. 12. significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase \> 500 u/l. 13. important primary or secondary immune dysfunction - eg. aids, severe neutropenia (neutrophiles \< 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc. 14. necessity of systemic antibiotic therapy in time of screening or inclusion to study. 15. female in reproductive age with positive pregnancy test during screening. 16. breast-feeding female. 17. female after menopause: 1. after an ovariohysterectomy 2. confirmed ovaries inactivity 3. menopause defined as at least 12 months after last menstruation or fsh \> 40 iu/l. 18. patients in severe systemic condition, it means comply at least on of the following: 1. need mechanical ventilation 2. ratio of pao2/fio2 lower than 200 mmhg 3. need the vasopressors, because of the shock 4. unconscious patients 19. taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0" 20. human immunodeficiency virus infection, active hepatitis b or c virus infection, fresh infection of cmv, ebv or influenza virus. 21. the co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol 22. lactose intolerance. 23. the inability to administration testing capsule. 24. other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.

1. age \< 18 years old. 2. inability to obtain informed consent. 3. patient's impaired consciousness in opinion of investigator. 4. swallowing difficulties before sars-cov 2 infection or related to sasrs-cov 2 infection (eg. caused by dyspnea). 5. severe food allergy. 6. at least 7 points in covid-19 performance status. 7. patients, who need blood transfusion in the day of study inclusion. 8. significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before covid 19 diagnosis. 9. stoma, perforation or abscess located in gastrointestinal tract area in the past. 10. clinical significant systemic or localised infections, other than covid 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect. 11. severe cardiac failure (nyha iii or more) before covid 19 diagnosis. 12. significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase \> 500 u/l. 13. important primary or secondary immune dysfunction - eg. aids, severe neutropenia (neutrophiles \< 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc. 14. necessity of systemic antibiotic therapy in time of screening or inclusion to study. 15. female in reproductive age with positive pregnancy test during screening. 16. breast-feeding female. 17. female after menopause: 1. after an ovariohysterectomy 2. confirmed ovaries inactivity 3. menopause defined as at least 12 months after last menstruation or fsh \> 40 iu/l. 18. patients in severe systemic condition, it means comply at least on of the following: 1. need mechanical ventilation 2. ratio of pao2/fio2 lower than 200 mmhg 3. need the vasopressors, because of the shock 4. unconscious patients 19. taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0" 20. human immunodeficiency virus infection, active hepatitis b or c virus infection, fresh infection of cmv, ebv or influenza virus. 21. the co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol 22. lactose intolerance. 23. the inability to administration testing capsule. 24. other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.

age < 18 years old. inability to obtain informed consent. patient's impaired consciousness in opinion of investigator. swallowing difficulties before sars-cov 2 infection or related to sasrs-cov 2 infection (eg. caused by dyspnea). severe food allergy. at least 7 points in covid-19 performance status. patients, who need blood transfusion in the day of study inclusion. significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before covid 19 diagnosis. stoma, perforation or abscess located in gastrointestinal tract area in the past. clinical significant systemic or localised infections, other than covid 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect. severe cardiac failure (nyha iii or more) before covid 19 diagnosis. significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase > 500 u/l. important primary or secondary immune dysfunction - eg. aids, severe neutropenia (neutrophiles < 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc. necessity of systemic antibiotic therapy in time of screening or inclusion to study. female in reproductive age with positive pregnancy test during screening. breast-feeding female. female after menopause: after an ovariohysterectomy confirmed ovaries inactivity menopause defined as at least 12 months after last menstruation or fsh > 40 iu/l. patients in severe systemic condition, it means comply at least on of the following: need mechanical ventilation ratio of pao2/fio2 lower than 200 mmhg need the vasopressors, because of the shock unconscious patients taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0" human immunodeficiency virus infection, active hepatitis b or c virus infection, fresh infection of cmv, ebv or influenza virus. the co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol lactose intolerance. the inability to administration testing capsule. other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.

age < 18 years old. inability to obtain informed consent. patient's impaired consciousness in opinion of investigator. swallowing difficulties before sars-cov 2 infection or related to sasrs-cov 2 infection (eg. caused by dyspnea). severe food allergy. at least 7 points in covid-19 performance status. patients, who need blood transfusion in the day of study inclusion. significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before covid 19 diagnosis. stoma, perforation or abscess located in gastrointestinal tract area in the past. clinical significant systemic or localised infections, other than covid 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect. severe cardiac failure (nyha iii or more) before covid 19 diagnosis. significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase > 500 u/l. important primary or secondary immune dysfunction - eg. aids, severe neutropenia (neutrophiles < 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc. necessity of systemic antibiotic therapy in time of screening or inclusion to study. female in reproductive age with positive pregnancy test during screening. breast-feeding female. female after menopause: after an ovariohysterectomy confirmed ovaries inactivity menopause defined as at least 12 months after last menstruation or fsh > 40 iu/l. patients in severe systemic condition, it means comply at least on of the following: need mechanical ventilation ratio of pao2/fio2 lower than 200 mmhg need the vasopressors, because of the shock unconscious patients taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0" human immunodeficiency virus infection, active hepatitis b or c virus infection, fresh infection of cmv, ebv or influenza virus. the co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol lactose intolerance. the inability to administration testing capsule. other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.

1. age < 18 years old. 2. inability to obtain informed consent. 3. patient's impaired consciousness in opinion of investigator. 4. swallowing difficulties before sars-cov 2 infection or related to sasrs-cov 2 infection (eg. caused by dyspnea). 5. severe food allergy. 6. at least 7 points in covid-19 performance status. 7. patients, who need blood transfusion in the day of study inclusion. 8. significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before covid 19 diagnosis. 9. stoma, perforation or abscess located in gastrointestinal tract area in the past. 10. clinical significant systemic or localised infections, other than covid 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect. 11. severe cardiac failure (nyha iii or more) before covid 19 diagnosis. 12. significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase > 500 u/l. 13. important primary or secondary immune dysfunction - eg. aids, severe neutropenia (neutrophiles < 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc. 14. necessity of systemic antibiotic therapy in time of screening or inclusion to study. 15. female in reproductive age with positive pregnancy test during screening. 16. breast-feeding female. 17. female after menopause: 1. after an ovariohysterectomy 2. confirmed ovaries inactivity 3. menopause defined as at least 12 months after last menstruation or fsh > 40 iu/l. 18. patients in severe systemic condition, it means comply at least on of the following: 1. need mechanical ventilation 2. ratio of pao2/fio2 lower than 200 mmhg 3. need the vasopressors, because of the shock 4. unconscious patients 19. taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0" 20. human immunodeficiency virus infection, active hepatitis b or c virus infection, fresh infection of cmv, ebv or influenza virus. 21. the co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol 22. lactose intolerance. 23. the inability to administration testing capsule. 24. other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.

1. age < 18 years old. 2. inability to obtain informed consent. 3. patient's impaired consciousness in opinion of investigator. 4. swallowing difficulties before sars-cov 2 infection or related to sasrs-cov 2 infection (eg. caused by dyspnea). 5. severe food allergy. 6. at least 7 points in covid-19 performance status. 7. patients, who need blood transfusion in the day of study inclusion. 8. significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before covid 19 diagnosis. 9. stoma, perforation or abscess located in gastrointestinal tract area in the past. 10. clinical significant systemic or localised infections, other than covid 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect. 11. severe cardiac failure (nyha iii or more) before covid 19 diagnosis. 12. significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase > 500 u/l. 13. important primary or secondary immune dysfunction - eg. aids, severe neutropenia (neutrophiles < 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc. 14. necessity of systemic antibiotic therapy in time of screening or inclusion to study. 15. female in reproductive age with positive pregnancy test during screening. 16. breast-feeding female. 17. female after menopause: 1. after an ovariohysterectomy 2. confirmed ovaries inactivity 3. menopause defined as at least 12 months after last menstruation or fsh > 40 iu/l. 18. patients in severe systemic condition, it means comply at least on of the following: 1. need mechanical ventilation 2. ratio of pao2/fio2 lower than 200 mmhg 3. need the vasopressors, because of the shock 4. unconscious patients 19. taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0" 20. human immunodeficiency virus infection, active hepatitis b or c virus infection, fresh infection of cmv, ebv or influenza virus. 21. the co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol 22. lactose intolerance. 23. the inability to administration testing capsule. 24. other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.